Throughout the last three months, 7 analysts have evaluated Silence Therapeutics (NASDAQ:SLN), offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.57, a high estimate of $75.00, and a low estimate of $49.00. Surpassing the previous average price target of $63.14, the current average has increased by 3.85%.

Diving into Analyst Ratings: An In-Depth Exploration

The...